Multiple Sclerosis Clinical Trial

A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring

Summary

The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Diagnosis of Multiple sclerosis (MS)
Currently or recently pregnant
Reside in a country where ozanimod is prescribed for treatment of MS

Exclusion Criteria:

Diagnostic prenatal test results known prior to first contact with the Registry Coordination Center (RCC)
Exposure to known teratogens and/or investigational medications during pregnancy

Other protocol-defined inclusion/exclusion criteria apply

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

1182

Study ID:

NCT05170126

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Evidera
Bethesda Maryland, 20814, United States More Info
Kristin Veley, Site 0001
Contact
Local Institution - 0002
Herne , 44625, Germany More Info
Site 0002
Contact

How clear is this clinincal trial information?

Study is for people with:

Multiple Sclerosis

Estimated Enrollment:

1182

Study ID:

NCT05170126

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.